{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:10:41Z","timestamp":1792815041638,"version":"4.5.0"},"reference-count":292,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.bmc.2023.117339","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T19:17:01Z","timestamp":1684610221000},"page":"117339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Recent developments in antimalarial drug discovery"],"prefix":"10.1016","volume":"88-89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9607","authenticated-orcid":false,"given":"Th\u00e9oneste","family":"Umumararungu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Bosco","family":"Nkuranga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gratien","family":"Habarurema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Baptiste","family":"Nyandwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jeanne","family":"Mukazayire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janvier","family":"Mukiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Muganga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocent","family":"Hahirwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matabishi","family":"Mpenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain Nyirimigabo","family":"Katembezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel Oladayo","family":"Olawode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egide","family":"Kayitare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Claver","family":"Kayumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2023.117339_b0005","unstructured":"World Malaria Report 2019 - World | ReliefWeb. Accessed May 24, 2022. https:\/\/reliefweb.int\/report\/world\/world-malaria-report-2019."},{"key":"10.1016\/j.bmc.2023.117339_b0010","unstructured":"World malaria report 2022. Accessed January 9, 2023. https:\/\/www.who.int\/publications-detail-redirect\/9789240064898."},{"key":"10.1016\/j.bmc.2023.117339_b0015","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/trstmh\/tru199","article-title":"Evolution from double to triple-antimalarial drug combinations","volume":"109","author":"Shanks","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.bmc.2023.117339_b0020","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ejmech.2016.11.025","article-title":"Comprehensive review on various strategies for antimalarial drug discovery","volume":"125","author":"Mishra","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.50","article-title":"Malaria","volume":"3","author":"Phillips","year":"2017","journal-title":"Nat Rev Dis Primer."},{"key":"10.1016\/j.bmc.2023.117339_b0030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1039\/C7MD00637C","article-title":"Recent updates in the discovery and development of novel antimalarial drug candidates","volume":"9","author":"Okombo","year":"2018","journal-title":"MedChemComm."},{"key":"10.1016\/j.bmc.2023.117339_b0035","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40265-018-0911-9","article-title":"Drugs in Development for Malaria","volume":"78","author":"Ashley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2023.117339_b0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12936-019-2724-z","article-title":"The past, present and future of anti-malarial medicines","volume":"18","author":"Tse","year":"2019","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2023.117339_b0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nrd4573","article-title":"Malaria medicines: a glass half full?","volume":"14","author":"Wells","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2023.117339_b0050","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cell.2017.06.030","article-title":"Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes","volume":"170","author":"Bushell","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2023.117339_b0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1126\/science.aan4472","article-title":"Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics","volume":"359","author":"Cowell","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bmc.2023.117339_b0060","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrd.2016.154","article-title":"Open data in drug discovery and development: lessons from malaria","volume":"15","author":"Wells","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2023.117339_b0065","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1128\/AAC.02883-15","article-title":"Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development","volume":"60","author":"McCarthy","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"Burrows","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2023.117339_b0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.chom.2019.06.001","article-title":"Elucidating Mechanisms of Drug-Resistant Plasmodium falciparum","volume":"26","author":"Ross","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bmc.2023.117339_b0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1286-4579(01)01524-6","article-title":"Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs","volume":"4","author":"Hyde","year":"2002","journal-title":"Microbes Infect"},{"key":"10.1016\/j.bmc.2023.117339_b0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4269\/ajtmh.2004.70.461","article-title":"Polymorphism of the Plasmodium falciparum multidrug resistance and chloroquine resistance transporter genes and in vitro susceptibility to aminoquinolines in isolates from the Peruvian Amazon","volume":"70","author":"Huaman","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2023.117339_b0090","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.4269\/ajtmh.14-0605","article-title":"Polymorphisms in the K13-Propeller Gene in Artemisinin-Susceptible Plasmodium falciparum Parasites from Bougoula-Hameau and Bandiagara, Mali","volume":"92","author":"Ouattara","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2023.117339_b0095","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.pt.2016.04.014","article-title":"Phenotypic screens in antimalarial drug discovery","volume":"32","author":"Hovlid","year":"2016","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.bmc.2023.117339_b0100","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2174\/156802612799362968","article-title":"Reversed Chloroquine Molecules as a Strategy to Overcome Resistance in Malaria","volume":"12","author":"Peyton","year":"2012","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0105","unstructured":"The Making of a Tropical Disease | Hopkins Press. Accessed May 24, 2022. https:\/\/www.press.jhu.edu\/books\/title\/12383\/making-tropical-disease."},{"key":"10.1016\/j.bmc.2023.117339_b0110","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2174\/0929867033457494","article-title":"Perspective in antimalarial chemotherapy","volume":"10","author":"Kumar","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0115","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nrmicro2331","article-title":"Artemisinin resistance: current status and scenarios for containment","volume":"8","author":"Dondorp","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmc.2023.117339_b0120","doi-asserted-by":"crossref","first-page":"e1002380","DOI":"10.1371\/journal.pbio.1002380","article-title":"Tools and Strategies for Malaria Control and Elimination: What Do We Need to Achieve a Grand Convergence in Malaria?","volume":"14","author":"Hemingway","year":"2016","journal-title":"PLoS Biol"},{"key":"10.1016\/j.bmc.2023.117339_b0125","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1128\/AAC.45.11.3171-3174.2001","article-title":"Reversal of Chloroquine Resistance in Plasmodium falciparum Using Combinations of Chemosensitizers","volume":"45","author":"van Schalkwyk","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0130","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1021\/jm010549o","article-title":"Design, synthesis, and evaluation of new chemosensitizers in multi-drug-resistant Plasmodium falciparum","volume":"45","author":"Guan","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0135","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1126\/science.3317830","article-title":"Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance","volume":"238","author":"Krogstad","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.bmc.2023.117339_b0140","first-page":"211","article-title":"Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum","volume":"9","author":"van Schalkwyk","year":"2006","journal-title":"Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother."},{"key":"10.1016\/j.bmc.2023.117339_b0145","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.3544220","article-title":"Reversal of chloroquine resistance in Plasmodium falciparum by verapamil","volume":"235","author":"Martin","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.bmc.2023.117339_b0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.parint.2009.04.004","article-title":"Spread and evolution of Plasmodium falciparum drug resistance","volume":"58","author":"Mita","year":"2009","journal-title":"Parasitol Int"},{"key":"10.1016\/j.bmc.2023.117339_b0155","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1017\/S0031182013000954","article-title":"Genetic and genomic approaches for the discovery of parasite genes involved in antimalarial drug resistance","volume":"140","author":"Mwangi","year":"2013","journal-title":"Parasitology"},{"key":"10.1016\/j.bmc.2023.117339_b0160","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.01677-08","article-title":"Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria","volume":"53","author":"Bacon","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0165","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm.4381","article-title":"Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic","volume":"23","author":"Blasco","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2023.117339_b0170","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/cmdc.201600298","article-title":"Discovery and Characterization of ACT-451840: an Antimalarial Drug with a Novel Mechanism of Action","volume":"11","author":"Boss","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2023.117339_b0175","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2165\/00003495-199652060-00004","article-title":"Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria","volume":"52","author":"de Vries","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2023.117339_b0180","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/s41467-020-15440-4","article-title":"Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway","volume":"11","author":"LaMonte","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2023.117339_b0185","doi-asserted-by":"crossref","first-page":"eaad9735","DOI":"10.1126\/scitranslmed.aad9735","article-title":"Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase","volume":"9","author":"Paquet","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmc.2023.117339_b0190","doi-asserted-by":"crossref","first-page":"16823","DOI":"10.1073\/pnas.1204556109","article-title":"Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target","volume":"109","author":"Yuthavong","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2023.117339_b0195","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.4155\/fmc.13.113","article-title":"Hemozoin and antimalarial drug discovery","volume":"5","author":"Fong","year":"2013","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0200","doi-asserted-by":"crossref","first-page":"eabg6013","DOI":"10.1126\/scitranslmed.abg6013","article-title":"The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance","volume":"13","author":"Murithi","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmc.2023.117339_b0205","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1021\/acs.jmedchem.1c01995","article-title":"Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria","volume":"65","author":"Taft","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0210","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.pt.2022.06.005","article-title":"Keystone Malaria Symposium 2022: a vibrant discussion of progress made and challenges ahead from drug discovery to treatment","volume":"38","author":"Kanai","year":"2022","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.bmc.2023.117339_b0215","unstructured":"GSK701 | Medicines for Malaria Venture. Accessed January 12, 2023. https:\/\/www.mmv.org\/node\/14221\/overlay."},{"key":"10.1016\/j.bmc.2023.117339_b0220","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.4155\/bio-2021-0194","article-title":"Simultaneous estimation of ZY-19489 and its active metabolite ZY-20486 in human plasma using LC-MS\/MS, a novel antimalarial compound","volume":"13","author":"Ghoghari","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.bmc.2023.117339_b0225","doi-asserted-by":"crossref","first-page":"E5455","DOI":"10.1073\/pnas.1414221111","article-title":"(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium","volume":"111","author":"Jim\u00e9nez-D\u00edaz","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmc.2023.117339_b0230","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13543784.2019.1560419","article-title":"AQ-13 - an investigational antimalarial drug","volume":"28","author":"Mengue","year":"2019","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.bmc.2023.117339_b0235","doi-asserted-by":"crossref","first-page":"27806","DOI":"10.1038\/srep27806","article-title":"Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor","volume":"6","author":"Goldgof","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2023.117339_b0240","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood-2016-11-748053","article-title":"Syk inhibitors interfere with erythrocyte membrane modification during P. falciparum growth and suppress parasite egress","volume":"130","author":"Pantaleo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2023.117339_b0245","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.3390\/ijms21197009","article-title":"Syk Inhibitors: New Computational Insights into Their Intraerythrocytic Action in Plasmodium falciparum Malaria","volume":"21","author":"Marchetti","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2023.117339_b0250","doi-asserted-by":"crossref","first-page":"e0164895","DOI":"10.1371\/journal.pone.0164895","article-title":"Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates Parasitemia","volume":"11","author":"Kesely","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2023.117339_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BST0340001","article-title":"The life and death of translation elongation factor 2","volume":"34","author":"J\u00f8rgensen","year":"2006","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.bmc.2023.117339_b0260","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.exppara.2007.01.005","article-title":"A non-radiolabeled heme-GSH interaction test for the screening of antimalarial compounds","volume":"116","author":"Garavito","year":"2007","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.bmc.2023.117339_b0265","doi-asserted-by":"crossref","first-page":"e0172718","DOI":"10.1371\/journal.pone.0172718","article-title":"Effects of sevuparin on rosette formation and cytoadherence of Plasmodium falciparum infected erythrocytes","volume":"12","author":"Saiwaew","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2023.117339_b0270","doi-asserted-by":"crossref","first-page":"e0188754","DOI":"10.1371\/journal.pone.0188754","article-title":"Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria","volume":"12","author":"Leitgeb","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2023.117339_b0275","doi-asserted-by":"crossref","first-page":"e0118898","DOI":"10.1371\/journal.pone.0118898","article-title":"Binding of subdomains 1\/2 of PfEMP1-DBL1\u03b1 to heparan sulfate or heparin mediates Plasmodium falciparum rosetting","volume":"10","author":"Angeletti","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2023.117339_b0280","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12936-017-1858-0","article-title":"Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria","volume":"16","author":"Varo","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2023.117339_b0285","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1021\/jm200592f","article-title":"Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential","volume":"54","author":"Coteron","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0290","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2174\/187152610791163336","article-title":"Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy","volume":"10","author":"Phillips","year":"2010","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.bmc.2023.117339_b0295","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.abb.2017.06.019","article-title":"The dihydroorotate dehydrogenases: Past and present","volume":"632","author":"Reis","year":"2017","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.bmc.2023.117339_b0300","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.2147\/DDDT.S265602","article-title":"Recent Progress in the Development of New Antimalarial Drugs with Novel Targets","volume":"14","author":"Belete","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmc.2023.117339_b0305","first-page":"2900","article-title":"Ferroquine, an ingenious antimalarial drug: thoughts on the mechanism of action","volume":"13","author":"Dubar","year":"2008","journal-title":"Mol Basel Switz."},{"key":"10.1016\/j.bmc.2023.117339_b0310","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1128\/AAC.00060-08","article-title":"In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum","volume":"52","author":"Henry","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0315","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1475-2875-6-81","article-title":"In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border","volume":"6","author":"Barends","year":"2007","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2023.117339_b0320","doi-asserted-by":"crossref","unstructured":"System-wide biochemical analysis reveals ozonide antimalarials initially act by disrupting Plasmodium falciparum haemoglobin digestion. PLoS. pathogens. doi: 10.1371\/journal.ppat.1008485.","DOI":"10.1371\/journal.ppat.1008485"},{"key":"10.1016\/j.bmc.2023.117339_b0325","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/acsinfecdis.5b00090","article-title":"Monoclonal Antibodies That Recognize the Alkylation Signature of Antimalarial Ozonides OZ277 (Arterolane) and OZ439 (Artefenomel)","volume":"2","author":"Jourdan","year":"2016","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2018.05.006","article-title":"The antimalarial pipeline","volume":"42","author":"Hooft van Huijsduijnen","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b0335","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1475-2875-6-70","article-title":"Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria","volume":"6","author":"Na-Bangchang","year":"2007","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2023.117339_b0340","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bmc.2023.117339_b0345","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1126\/science.285.5433.1573","article-title":"Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs","volume":"285","author":"Jomaa","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bmc.2023.117339_b0350","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4103\/2141-9248.139270","article-title":"Fixed Dose Combination of Arterolane and Piperaquine: A Newer Prospect in Antimalarial Therapy","volume":"4","author":"Patil","year":"2014","journal-title":"Ann Med Health Sci Res"},{"key":"10.1016\/j.bmc.2023.117339_b0355","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1128\/AAC.01064-06","article-title":"Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277)","volume":"51","author":"Uhlemann","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0360","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1128\/AAC.43.3.598","article-title":"8-Aminoquinolines Active against Blood Stage Plasmodium falciparum In Vitro Inhibit Hematin Polymerization","volume":"43","author":"Vennerstrom","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0365","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/AAC.00343-15","article-title":"Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics","volume":"59","author":"Vuong","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0370","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2147\/DDDT.S61443","article-title":"Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date","volume":"10","author":"Ebstie","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmc.2023.117339_b0375","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1590\/0001-3765201520140637","article-title":"Effects of primaquine and chloroquine on oxidative stress parameters in rats","volume":"87","author":"Giovanella","year":"2015","journal-title":"An Acad Bras Cienc"},{"key":"10.1016\/j.bmc.2023.117339_b0380","doi-asserted-by":"crossref","unstructured":"Gaur AH, McCarthy JS, Panetta JC, et al. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: A first-in-human and induced blood-stage malaria phase 1a\/b trial. Lancet Infect Dis. Published online. April;7:2020. doi: 10.1016\/S1473-3099(19)30611-5.","DOI":"10.1016\/S1473-3099(19)30611-5"},{"key":"10.1016\/j.bmc.2023.117339_b0385","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpddr.2019.02.004","article-title":"Plasmodium knowlesi exhibits distinct in vitro drug susceptibility profiles from those of Plasmodium falciparum","volume":"9","author":"van Schalkwyk","year":"2019","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.bmc.2023.117339_b0390","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.chom.2012.12.006","article-title":"Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials","volume":"13","author":"Spillman","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bmc.2023.117339_b0395","doi-asserted-by":"crossref","first-page":"e0178163","DOI":"10.1371\/journal.pone.0178163","article-title":"Plasmid-free CRISPR\/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733","volume":"12","author":"Crawford","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2023.117339_b0400","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1193225","article-title":"Spiroindolones, a potent compound class for the treatment of malaria","volume":"329","author":"Rottmann","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bmc.2023.117339_b0405","unstructured":"A 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4. Accessed May 10, 2020. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6635429\/."},{"key":"10.1016\/j.bmc.2023.117339_b0410","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1038\/ncomms6521","article-title":"Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum","volume":"5","author":"Vaidya","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2023.117339_b0415","doi-asserted-by":"crossref","unstructured":"Flannery EL, McNamara CW, Kim SW, et al. Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials. ACS Chem Biol. 2015;10(2):413-420. doi:10.1021\/cb500616x.","DOI":"10.1021\/cb500616x"},{"key":"10.1016\/j.bmc.2023.117339_b0420","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/mmi.12765","article-title":"Diverse chemotypes disrupt ion homeostasis in the Malaria parasite","volume":"94","author":"Lehane","year":"2014","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.bmc.2023.117339_b0425","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12936-015-0957-z","article-title":"Reduced deformability of parasitized red blood cells as a biomarker for anti-malarial drug efficacy","volume":"14","author":"Deng","year":"2015","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2023.117339_b0430","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/infdis\/jiv358","article-title":"A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609","volume":"213","author":"Zhang","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b0435","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1473-3099(17)30171-8","article-title":"Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a\/1b randomised study","volume":"17","author":"McCarthy","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b0440","doi-asserted-by":"crossref","first-page":"e1002138","DOI":"10.1371\/journal.pmed.1002138","article-title":"Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling","volume":"13","author":"Le Bihan","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.bmc.2023.117339_b0445","doi-asserted-by":"crossref","first-page":"22576","DOI":"10.1074\/jbc.M113.453159","article-title":"UV-triggered affinity capture identifies interactions between the Plasmodium falciparum multidrug resistance protein 1 (PfMDR1) and antimalarial agents in live parasitized cells","volume":"288","author":"Brunner","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0450","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/mmi.13397","article-title":"CRISPR-Cas9-modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs","volume":"101","author":"Ng","year":"2016","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.bmc.2023.117339_b0455","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.04125-14","article-title":"First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity","volume":"59","author":"Bruderer","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0460","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bcp.12962","article-title":"Pharmacokinetic\/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects","volume":"82","author":"Krause","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b0465","doi-asserted-by":"crossref","unstructured":"Berliner RW, Earle DP, Taggart JV, et al. Studies on the chemotherapy of the human malarias. VI. The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline 12. J Clin Invest. 1948;27(3 Pt 2):98-107.","DOI":"10.1172\/JCI101980"},{"key":"10.1016\/j.bmc.2023.117339_b0470","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4269\/ajtmh.1996.55.579","article-title":"Aminoquinolines that circumvent resistance in Plasmodium falciparum in vitro","volume":"55","author":"De","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2023.117339_b0475","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1021\/jm980146x","article-title":"Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines","volume":"41","author":"De","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0480","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1128\/AAC.00675-10","article-title":"4-aminoquinolines active against chloroquine-resistant Plasmodium falciparum: basis of antiparasite activity and quantitative structure-activity relationship analyses","volume":"55","author":"Hocart","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0485","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0001-706X(94)90053-1","article-title":"Uptake and efflux of chloroquine by chloroquine-resistant Plasmodium falciparum clones recently isolated in Africa","volume":"58","author":"Bayoumi","year":"1994","journal-title":"Acta Trop"},{"key":"10.1016\/j.bmc.2023.117339_b0490","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1128\/AAC.01061-12","article-title":"Novel 4-aminoquinoline analogs highly active against the blood and sexual stages of Plasmodium in vivo and in vitro","volume":"56","author":"S\u00e1enz","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0495","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/jac\/dkab219","article-title":"Cross-resistance of the chloroquine-derivative AQ-13 with amodiaquine in Cambodian Plasmodium falciparum isolates","volume":"76","author":"Nardella","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.bmc.2023.117339_b0500","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.11.5.826","article-title":"Activities of various 4-aminoquinolines against infections with chloroquine-resistant strains of Plasmodium falciparum","volume":"11","author":"Lh","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0505","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10915810490471352","article-title":"Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques","volume":"23","author":"Ramanathan-Girish","year":"2004","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.bmc.2023.117339_b0510","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1371\/journal.pctr.0020006","article-title":"Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers","volume":"2","author":"Mzayek","year":"2007","journal-title":"PLoS Clin Trials"},{"key":"10.1016\/j.bmc.2023.117339_b0515","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1473-3099(17)30365-1","article-title":"AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial","volume":"17","author":"Koita","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b0520","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jchromb.2005.12.011","article-title":"Sensitive fluorescence HPLC assay for AQ-13, a candidate aminoquinoline antimalarial, that also detects chloroquine and N-dealkylated metabolites","volume":"833","author":"Deng","year":"2006","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.bmc.2023.117339_b0525","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/00034983.1984.11811868","article-title":"In vitro assessment of the antimalarial activity of chloroquine and its major metabolites","volume":"78","author":"Aderounmu","year":"1984","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.bmc.2023.117339_b0530","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/em.1052","article-title":"Genetic toxicology testing of the antimalarial drugs chloroquine and a new analog, AQ-13","volume":"38","author":"Riccio","year":"2001","journal-title":"Environ Mol Mutagen"},{"key":"10.1016\/j.bmc.2023.117339_b0535","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1073\/pnas.1015762108","article-title":"Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria","volume":"108","author":"Charman","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmc.2023.117339_b0540","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1021\/jm400004u","article-title":"Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres","volume":"56","author":"Wang","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0545","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2125.2012.04368.x","article-title":"First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials","volume":"75","author":"Moehrle","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b0550","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1473-3099(15)00320-5","article-title":"Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial","volume":"16","author":"Phyo","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b0555","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1021\/acs.jmedchem.7b00299","article-title":"Seeking the Elusive Long-Acting Ozonide: Discovery of Artefenomel (OZ439)","volume":"60","author":"Kim","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0560","doi-asserted-by":"crossref","unstructured":"Lm U, Pm B, Ts C, et al. Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations. Antimicrobial agents and chemotherapy. doi:10.1128\/AAC.03942-14.","DOI":"10.1128\/AAC.03942-14"},{"key":"10.1016\/j.bmc.2023.117339_b0565","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1128\/AAC.00283-12","article-title":"Comparative Ex Vivo Activity of Novel Endoperoxides in Multidrug-Resistant Plasmodium falciparum and P. vivax","volume":"56","author":"Marfurt","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0570","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI98012","article-title":"A controlled human malaria infection model enabling evaluation of transmission-blocking interventions","volume":"128","author":"Collins","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmc.2023.117339_b0575","doi-asserted-by":"crossref","unstructured":"Collins KA, Abd-Rahman AN, Marquart L, et al. Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection. J Infect Dis. doi: 10.1093\/infdis\/jiaa287.","DOI":"10.1093\/infdis\/jiaa287"},{"key":"10.1016\/j.bmc.2023.117339_b0580","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01566-17","article-title":"Parasite-Mediated Degradation of Synthetic Ozonide Antimalarials Impacts In Vitro Antimalarial Activity","volume":"62","author":"Giannangelo","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0585","doi-asserted-by":"crossref","unstructured":"A S, K I, Pd R. Endoperoxide Drug Cross-Resistance Patterns for Plasmodium falciparum Exhibiting an Artemisinin Delayed-Clearance Phenotype. Antimicrobial agents and chemotherapy. doi:10.1128\/AAC.00857-16.","DOI":"10.1128\/AAC.00857-16"},{"key":"10.1016\/j.bmc.2023.117339_b0590","doi-asserted-by":"crossref","unstructured":"F B, J J, C S, et al. In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate. Malaria journal. doi:10.1186\/s12936-017-1696-0.","DOI":"10.1186\/s12936-017-1696-0"},{"key":"10.1016\/j.bmc.2023.117339_b0595","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.1260867","article-title":"K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates","volume":"347","author":"Straimer","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bmc.2023.117339_b0600","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00172-17","article-title":"Plasmodium falciparum K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness In Vitro","volume":"8","author":"Straimer","year":"2017","journal-title":"MBio"},{"key":"10.1016\/j.bmc.2023.117339_b0605","doi-asserted-by":"crossref","unstructured":"Rl C, Tl E, M L, et al. Improved safety margin for embryotoxicity in rats for the new endoperoxide artefenomel (OZ439) as compared to artesunate. Birth defects research. doi:10.1002\/bdr2.1170.","DOI":"10.1002\/bdr2.1170"},{"key":"10.1016\/j.bmc.2023.117339_b0610","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01371-19","article-title":"A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers","volume":"64","author":"McCarthy","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0615","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acs.molpharmaceut.8b01333","article-title":"Impact of Ferroquine on the Solubilization of Artefenomel (OZ439) during in Vitro Lipolysis in Milk and Implications for Oral Combination Therapy for Malaria","volume":"16","author":"Salim","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmc.2023.117339_b0620","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1021\/acs.molpharmaceut.0c00475","article-title":"Lipid Compositions in Infant Formulas Affect the Solubilization of Antimalarial Drugs Artefenomel (OZ439) and Ferroquine during Digestion","volume":"17","author":"Salim","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmc.2023.117339_b0625","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12916-017-0940-3","article-title":"A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria","volume":"15","author":"Macintyre","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.bmc.2023.117339_b0630","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1021\/acs.jmedchem.6b01586","article-title":"Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439)","volume":"60","author":"Dong","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0635","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1124\/dmd.115.069187","article-title":"KAE609 (Cipargamin), a New Spiroindolone Agent for the Treatment of Malaria: Evaluation of the Absorption, Distribution, Metabolism, and Excretion of a Single Oral 300-mg Dose of [14C]KAE609 in Healthy Male Subjects","volume":"44","author":"Huskey","year":"2016","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"10.1016\/j.bmc.2023.117339_b0640","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/microbiolspec.EI10-0013-2016","article-title":"Artemisinin-Resistant Plasmodium falciparum Malaria","volume":"4","author":"Fairhurst","year":"2016","journal-title":"Microbiol Spectr."},{"key":"10.1016\/j.bmc.2023.117339_b0645","doi-asserted-by":"crossref","first-page":"e00087","DOI":"10.1128\/AAC.00087-18","article-title":"Cell Swelling Induced by the Antimalarial KAE609 (Cipargamin) and Other PfATP4-Associated Antimalarials","volume":"62","author":"Dennis","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0650","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa1315860","article-title":"Spiroindolone KAE609 for falciparum and vivax malaria","volume":"371","author":"White","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2023.117339_b0655","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1021\/jm100410f","article-title":"Spirotetrahydro \u03b2-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria","volume":"53","author":"Yeung","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0660","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4155\/fmc.15.177","article-title":"Spiroindolone NITD609 is a novel antimalarial drug that targets the P-type ATPase PfATP4","volume":"8","author":"Turner","year":"2016","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0665","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1017\/S0031182013000747","article-title":"Progressing the global antimalarial portfolio: finding drugs which target multiple Plasmodium life stages","volume":"141","author":"Smith","year":"2014","journal-title":"Parasitology"},{"key":"10.1016\/j.bmc.2023.117339_b0670","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1128\/AAC.03393-14","article-title":"A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers","volume":"58","author":"Leong","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0675","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1128\/AAC.06377-11","article-title":"The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector","volume":"56","author":"van Pelt-Koops","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0680","doi-asserted-by":"crossref","unstructured":"Huskey SEW, Zhu C qi, Lin MM, et al. Identification of Three Novel Ring Expansion Metabolites of KAE609, a New Spiroindolone Agent for the Treatment of Malaria, in Rats, Dogs, and Humans. Drug Metab Dispos Biol Fate Chem. 2016;44(5):653-664. doi:10.1124\/dmd.115.069112.","DOI":"10.1124\/dmd.115.069112"},{"key":"10.1016\/j.bmc.2023.117339_b0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/372521","article-title":"Single Ascending Dose Safety and Pharmacokinetics of CDRI-97\/78: First-in-Human Study of a Novel Antimalarial Drug","volume":"2014","author":"Shafiq","year":"2014","journal-title":"Malar Res Treat."},{"key":"10.1016\/j.bmc.2023.117339_b0690","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12936-015-0684-5","article-title":"Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97\u201378 in rat plasma using the HPLC\u2013ESI-MS\/MS method: application to drug interaction study","volume":"14","author":"Wahajuddin","year":"2015","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2023.117339_b0695","doi-asserted-by":"crossref","first-page":"7581","DOI":"10.1021\/jm801006v","article-title":"Novel Bis- and Tris-1,2,4-trioxanes: Synthesis and Antimalarial Activity against Multidrug-Resistant Plasmodium yoelii in Swiss Mice","volume":"51","author":"Singh","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0700","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1055\/s-0033-1334921","article-title":"Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97\/78 following coadministration to rats","volume":"63","author":"Kushwaha","year":"2013","journal-title":"Drug Res."},{"key":"10.1016\/j.bmc.2023.117339_b0705","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3109\/00498254.2015.1017548","article-title":"Combined effect of rifampicin-induced P-glycoprotein expression and lipopolysaccharide-induced intestinal sepsis on the effective permeability and pharmacokinetics of an anti-malarial candidate CDRI 97\/78 in rats","volume":"45","author":"Singh","year":"2015","journal-title":"Xenobiotica Fate Foreign Compd Biol Syst."},{"key":"10.1016\/j.bmc.2023.117339_b0710","doi-asserted-by":"crossref","first-page":"E509","DOI":"10.3390\/pharmaceutics12060509","article-title":"Oral Administration of Artemisone for the Treatment of Schistosomiasis: Formulation Challenges and In Vivo Efficacy","volume":"12","author":"Zech","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.bmc.2023.117339_b0715","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/anie.200503071","article-title":"Artemisone\u2014A Highly Active Antimalarial Drug of the Artemisinin Class","volume":"45","author":"Haynes","year":"2006","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2023.117339_b0720","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1128\/AAC.00502-09","article-title":"Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model","volume":"53","author":"Dunay","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0725","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40249-016-0196-8","article-title":"Alternatives to currently used antimalarial drugs: in search of a magic bullet","volume":"5","author":"Bhagavathula","year":"2016","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.bmc.2023.117339_b0730","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijpddr.2017.05.002","article-title":"Elimination of Schistosoma mansoni in infected mice by slow release of artemisone","volume":"7","author":"Gold","year":"2017","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.bmc.2023.117339_b0735","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1128\/AAC.01585-07","article-title":"First Assessment in Humans of the Safety, Tolerability, Pharmacokinetics, and Ex Vivo Pharmacodynamic Antimalarial Activity of the New Artemisinin Derivative Artemisone","volume":"52","author":"Nagelschmitz","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0740","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13071-017-2018-7","article-title":"Controlled release of artemisone for the treatment of experimental cerebral malaria","volume":"10","author":"Golenser","year":"2017","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.bmc.2023.117339_b0745","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3389\/fphar.2020.00846","article-title":"Treatment of Experimental Cerebral Malaria by Slow Release of Artemisone From Injectable Pasty Formulation","volume":"11","author":"Golenser","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b0750","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkl563","article-title":"Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo","volume":"59","author":"Vivas","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0755","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nature14412","article-title":"A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria","volume":"520","author":"Mbengue","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2023.117339_b0760","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1128\/AAC.02462-14","article-title":"Ex Vivo Activity of Endoperoxide Antimalarials, Including Artemisone and Arterolane, against Multidrug-Resistant Plasmodium falciparum Isolates from Cambodia","volume":"58","author":"Lanteri","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0765","doi-asserted-by":"crossref","first-page":"e02214","DOI":"10.1128\/AAC.02214-17","article-title":"Artemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium falciparum Transmissible Gametocyte Stages","volume":"62","author":"Coertzen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0770","first-page":"515","article-title":"Fosmidomycin: a new phosphonic acid antibiotic. Part I: Phase I tolerance studies","volume":"23","author":"Kuemmerle","year":"1985","journal-title":"Int J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b0775","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/jac\/23.2.275","article-title":"Clindamycin treatment of falciparum malaria in Brazil","volume":"23","author":"Kremsner","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0780","doi-asserted-by":"crossref","first-page":"e1001138","DOI":"10.1371\/journal.pbio.1001138","article-title":"Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum","volume":"9","author":"Yeh","year":"2011","journal-title":"PLoS Biol"},{"key":"10.1016\/j.bmc.2023.117339_b0785","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1186\/gb-2009-10-2-r21","article-title":"Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum","volume":"10","author":"Dharia","year":"2009","journal-title":"Genome Biol"},{"key":"10.1016\/j.bmc.2023.117339_b0790","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1128\/EC.00160-14","article-title":"Isoprenoid biosynthesis in Plasmodium falciparum","volume":"13","author":"Guggisberg","year":"2014","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.bmc.2023.117339_b0795","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1128\/AAC.47.2.735-738.2003","article-title":"Fosmidomycin, a Novel Chemotherapeutic Agent for Malaria","volume":"47","author":"Lell","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0800","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ejmech.2006.06.015","article-title":"Arylmethyl substituted derivatives of Fosmidomycin: Synthesis and antimalarial activity","volume":"41","author":"Schl\u00fcter","year":"2006","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0805","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1128\/AAC.01448-06","article-title":"Randomized Controlled Trial of Fosmidomycin-Clindamycin versus Sulfadoxine-Pyrimethamine in the Treatment of Plasmodium falciparum Malaria","volume":"51","author":"Oyakhirome","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0810","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1128\/AAC.46.9.2889-2894.2002","article-title":"In Vitro and In Vivo Synergy of Fosmidomycin, a Novel Antimalarial Drug, with Clindamycin","volume":"46","author":"Wiesner","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0815","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1021\/acs.jmedchem.8b01026","article-title":"MEPicides: \u03b1, \u03b2-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria","volume":"61","author":"Wang","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0820","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2023.117339_b0825","doi-asserted-by":"crossref","unstructured":"Abstracts of the Oral and Poster Presentations During Haematocon 2014 (55th Annual Conference of Indian Society of Haematology & Blood Transfusion). Indian J Hematol Blood Transfus. 2014;30(S2):448-546. doi:10.1007\/s12288-014-0467-0.","DOI":"10.1007\/s12288-014-0467-0"},{"key":"10.1016\/j.bmc.2023.117339_b0830","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2015.05.007","article-title":"Tyrosine kinase inhibitors: New class of antimalarials on the horizon?","volume":"55","author":"Pathak","year":"2015","journal-title":"Blood Cell Mol Dis"},{"key":"10.1016\/j.bmc.2023.117339_b0835","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.freeradbiomed.2011.11.008","article-title":"New antimalarial indolone-N-oxides, generating radical species, destabilize the host cell membrane at early stages of Plasmodium falciparum growth: Role of band 3 tyrosine phosphorylation","volume":"52","author":"Pantaleo","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.bmc.2023.117339_b0840","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1182\/blood.V96.4.1550","article-title":"Sequential phosphorylation of protein band 3 by Syk and Lyn tyrosine kinases in intact human erythrocytes: identification of primary and secondary phosphorylation sites","volume":"96","author":"Brunati","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2023.117339_b0845","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1182\/blood-2010-11-317024","article-title":"Regulation of membrane-cytoskeletal interactions by tyrosine phosphorylation of erythrocyte band 3","volume":"117","author":"Ferru","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2023.117339_b0850","doi-asserted-by":"crossref","first-page":"e15847","DOI":"10.1371\/journal.pone.0015847","article-title":"Irreversible AE1 Tyrosine Phosphorylation Leads to Membrane Vesiculation in G6PD Deficient Red Cells","volume":"6","author":"Pantaleo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2023.117339_b0855","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.exppara.2013.03.022","article-title":"Chemosensitization potential of P-glycoprotein inhibitors in malaria parasites","volume":"134","author":"Alcantara","year":"2013","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.bmc.2023.117339_b0860","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1476-5381.2010.00946.x","article-title":"Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes","volume":"161","author":"Nebot","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b0865","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates","volume":"165","author":"Filppula","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b0870","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/dmd.112.048017","article-title":"Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response","volume":"41","author":"Filppula","year":"2013","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"10.1016\/j.bmc.2023.117339_b0875","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11095-020-02834-8","article-title":"Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib. In Vitro and In Vivo Disconnect","volume":"37","author":"Adiwidjaja","year":"2020","journal-title":"Pharm Res"},{"key":"10.1016\/j.bmc.2023.117339_b0880","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00280-003-0722-9","article-title":"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects","volume":"53","author":"Bolton","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b0885","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00280-004-0832-z","article-title":"Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects","volume":"54","author":"Dutreix","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b0890","doi-asserted-by":"crossref","unstructured":"Wang Z, Wang L, Xia M ming, et al. Pharmacokinetics Interaction between Imatinib and Genistein in Rats. BioMed Res Int. 2015;2015:368976. doi:10.1155\/2015\/368976.","DOI":"10.1155\/2015\/368976"},{"key":"10.1016\/j.bmc.2023.117339_b0895","doi-asserted-by":"crossref","first-page":"e20210724","DOI":"10.1084\/jem.20210724","article-title":"Imatinib augments standard malaria combination therapy without added toxicity","volume":"218","author":"Chien","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmc.2023.117339_b0900","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bmc.2023.117339_b0905","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ctrv.2010.04.008","article-title":"Practical management of tyrosine kinase inhibitor-associated side effects in GIST","volume":"37","author":"Joensuu","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bmc.2023.117339_b0910","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2023.117339_b0915","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/13543784.2018.1524871","article-title":"The early preclinical and clinical development of ganaplacide (KAF156), a novel antimalarial compound","volume":"27","author":"Koller","year":"2018","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.bmc.2023.117339_b0920","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJMoa1602250","article-title":"Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria","volume":"375","author":"White","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2023.117339_b0925","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1128\/AAC.02727-13","article-title":"KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission","volume":"58","author":"Kuhen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0930","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.1211936","article-title":"Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery","volume":"334","author":"Meister","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bmc.2023.117339_b0935","doi-asserted-by":"crossref","first-page":"16166","DOI":"10.1038\/nmicrobiol.2016.166","article-title":"UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes","volume":"1","author":"Lim","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.bmc.2023.117339_b0940","unstructured":"Antimalarial Agents - 1st Edition. Accessed June 3, 2022. https:\/\/www.elsevier.com\/books\/antimalarial-agents\/patrick\/978-0-08-101210-9."},{"key":"10.1016\/j.bmc.2023.117339_b0945","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12936-017-2162-8","article-title":"A phase 1 evaluation of the pharmacokinetic\/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine","volume":"17","author":"Leong","year":"2018","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2023.117339_b0950","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.drudis.2015.06.009","article-title":"Supporting malaria elimination with 21st century antimalarial agent drug discovery","volume":"20","author":"Diagana","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2023.117339_b0955","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","article-title":"A novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"522","author":"Baraga\u00f1a","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2023.117339_b0960","doi-asserted-by":"crossref","first-page":"9672","DOI":"10.1021\/acs.jmedchem.6b00723","article-title":"Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy","volume":"59","author":"Baraga\u00f1a","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b0965","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1021\/acsinfecdis.9b00144","article-title":"Flexible 3D Cell-Based Platforms for the Discovery and Profiling of Novel Drugs Targeting Plasmodium Hepatic Infection","volume":"5","author":"Arez","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b0970","doi-asserted-by":"crossref","DOI":"10.4172\/2472-4998.1000107","article-title":"A One-Stop Novel Drug for Malaria Treatment and Control","volume":"1","author":"Dash","year":"2016","journal-title":"J Emerg Infect Dis."},{"key":"10.1016\/j.bmc.2023.117339_b0975","doi-asserted-by":"crossref","first-page":"e02181","DOI":"10.1128\/AAC.02181-19","article-title":"Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor","volume":"64","author":"Rottmann","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0980","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S1473-3099(21)00252-8","volume":"21","author":"McCarthy","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b0985","doi-asserted-by":"crossref","first-page":"2325.e7","DOI":"10.1016\/j.neurobiolaging.2010.12.012","article-title":"Lest we forget you \u2014 methylene blue \u2026","volume":"32","author":"Schirmer","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bmc.2023.117339_b0990","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1128\/AAC.49.11.4592-4597.2005","article-title":"In Vitro Assessment of Methylene Blue on Chloroquine-Sensitive and -Resistant Plasmodium falciparum Strains Reveals Synergistic Action with Artemisinins","volume":"49","author":"Akoachere","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b0995","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12916-018-1045-3","article-title":"Efficacy and safety of methylene blue in the treatment of malaria: a systematic review","volume":"16","author":"Lu","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.bmc.2023.117339_b1000","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(03)15162-8","article-title":"Artesunate combinations for treatment of malaria: meta-analysis","volume":"363","author":"Adjuik","year":"2004","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.bmc.2023.117339_b1005","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1128\/AAC.39.12.2671","article-title":"Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines","volume":"39","author":"Vennerstrom","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b1010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1051\/parasite\/2007142135","article-title":"Blood schizontocidal activity of methylene blue in combination with antimalarials against Plasmodium falciparum","volume":"14","author":"Garavito","year":"2007","journal-title":"Parasite"},{"key":"10.1016\/j.bmc.2023.117339_b1015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-008-0563-x","article-title":"High absolute bioavailability of methylene blue given as an aqueous oral formulation","volume":"65","author":"Walter-Sack","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b1020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00428-009-0734-x","article-title":"Turquoise to dark green organs at autopsy","volume":"454","author":"Warth","year":"2009","journal-title":"Virchows Arch Int J Pathol."},{"key":"10.1016\/j.bmc.2023.117339_b1025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s002280000124","article-title":"Pharmacokinetics and organ distribution of intravenous and oral methylene blue","volume":"56","author":"Peter","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b1030","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.00773-07","article-title":"Interactions of Methylene Blue with Human Disulfide Reductases and Their Orthologues from Plasmodium falciparum","volume":"52","author":"Buchholz","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b1035","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1128\/AAC.00874-15","article-title":"Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax","volume":"59","author":"Wirjanata","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b1040","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/infdis\/jiu540","article-title":"Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso","volume":"211","author":"Coulibaly","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b1045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12936-018-2300-y","article-title":"Differential activity of methylene blue against erythrocytic and hepatic stages of Plasmodium","volume":"17","author":"Bosson-Vanga","year":"2018","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2023.117339_b1050","first-page":"272","article-title":"Methylene blue as an antimalarial agent","volume":"8","author":"Schirmer","year":"2003","journal-title":"Redox Rep Commun Free Radic Res."},{"key":"10.1016\/j.bmc.2023.117339_b1055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0014-5793(98)00031-3","article-title":"Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue","volume":"422","author":"F\u00e4rber","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bmc.2023.117339_b1060","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/pds.3370","article-title":"Haemolysis risk in methylene blue treatment of G6PD-sufficient and G6PD-deficient West-African children with uncomplicated falciparum malaria: a synopsis of four RCTs","volume":"22","author":"M\u00fcller","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.bmc.2023.117339_b1065","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1021\/jm3001373","article-title":"3,5-Diaryl-2-aminopyridines as a Novel Class of Orally Active Antimalarials Demonstrating Single Dose Cure in Mice and Clinical Candidate Potential","volume":"55","author":"Younis","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b1070","unstructured":"World Health Organization. World Malaria Report 2015. World Health Organization; 2015. Accessed January 7, 2023. https:\/\/apps.who.int\/iris\/handle\/10665\/200018."},{"key":"10.1016\/j.bmc.2023.117339_b1075","doi-asserted-by":"crossref","first-page":"e01896","DOI":"10.1128\/AAC.01896-19","article-title":"Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers","volume":"64","author":"Sinxadi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b1080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ddtec.2014.03.002","article-title":"Antimalarial drug resistance: new treatments options for Plasmodium","volume":"11","author":"Gamo","year":"2014","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.bmc.2023.117339_b1085","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/qua.25189","article-title":"Electronic structure and conformational analysis of P218: An antimalarial drug candidate","volume":"116","author":"Abbat","year":"2016","journal-title":"Int J Quantum Chem"},{"key":"10.1016\/j.bmc.2023.117339_b1090","doi-asserted-by":"crossref","first-page":"11221","DOI":"10.1021\/cr500543f","article-title":"Antimalarials in Development in 2014","volume":"114","author":"Barnett","year":"2014","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2023.117339_b1095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.molbiopara.2013.02.008","article-title":"Folate metabolism in human malaria parasites\u201475 years on","volume":"188","author":"M\u00fcller","year":"2013","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.bmc.2023.117339_b1100","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/jac\/dkl104","article-title":"The past, present and future of antifolates in the treatment of Plasmodium falciparum infection","volume":"57","author":"Nzila","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b1105","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/jcc.23719","article-title":"Importance of cytochromes in cyclization reactions: Quantum chemical study on a model reaction of proguanil to cycloguanil","volume":"35","author":"Arfeen","year":"2014","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmc.2023.117339_b1110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nsb921","article-title":"Insights into antifolate resistance from malarial DHFR-TS structures","volume":"10","author":"Yuvaniyama","year":"2003","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.bmc.2023.117339_b1115","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2174\/092986708784911551","article-title":"Modelling and informatics in the analysis of P. falciparum DHFR enzyme inhibitors","volume":"15","author":"Adane","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b1120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1286-4579(01)01525-8","article-title":"Basis for antifolate action and resistance in malaria","volume":"4","author":"Yuthavong","year":"2002","journal-title":"Microbes Infect"},{"key":"10.1016\/j.bmc.2023.117339_b1125","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.parint.2018.08.004","article-title":"Characterization of Plasmodium knowlesi dihydrofolate reductase-thymidylate synthase and sensitivity to antifolates","volume":"67","author":"Ittarat","year":"2018","journal-title":"Parasitol Int"},{"key":"10.1016\/j.bmc.2023.117339_b1130","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/bcp.14219","article-title":"First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection","volume":"86","author":"Chughlay","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b1135","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4269\/ajtmh.2011.10-0256","article-title":"Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates","volume":"84","author":"Leitgeb","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2023.117339_b1140","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjh.14303","article-title":"Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion","volume":"175","author":"Telen","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bmc.2023.117339_b1145","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/13543784.2015.1000483","article-title":"Antimalarial compounds in Phase II clinical development","volume":"24","author":"Held","year":"2015","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.bmc.2023.117339_b1150","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2023.117339_b1155","first-page":"4301","article-title":"Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies","volume":"125","author":"Chen","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.bmc.2023.117339_b1160","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1086\/605431","article-title":"Use of Peroxisome Proliferator-Activated Receptor \u03b3 Agonists as Adjunctive Treatment for Plasmodium falciparum Malaria: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"49","author":"Boggild","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b1165","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/eri.10.90","article-title":"Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria","volume":"8","author":"John","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.bmc.2023.117339_b1170","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1086\/598222","article-title":"Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria","volume":"199","author":"Serghides","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b1175","first-page":"6742","article-title":"Peroxisome proliferator-activated receptor gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes\/macrophages","volume":"166","author":"Serghides","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.bmc.2023.117339_b1180","doi-asserted-by":"crossref","first-page":"e1003980","DOI":"10.1371\/journal.ppat.1003980","article-title":"PPAR\u03b3 agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria","volume":"10","author":"Serghides","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bmc.2023.117339_b1185","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40262-016-0472-6","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus","volume":"56","author":"Akhlaghi","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bmc.2023.117339_b1190","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/jcph.497","article-title":"Pediatric drug development programs for type 2 diabetes: A review","volume":"55","author":"Christensen","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2023.117339_b1195","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1128\/IAI.72.10.5630-5637.2004","article-title":"Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls","volume":"72","author":"Lyke","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.bmc.2023.117339_b1200","first-page":"2759","article-title":"Host response to malaria during pregnancy: placental monocyte recruitment is associated with elevated beta chemokine expression","volume":"170","author":"Abrams","year":"2003","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.bmc.2023.117339_b1205","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/00034983.1996.11813068","article-title":"The pathogenesis of severe malaria in African children","volume":"90","author":"Marsh","year":"1996","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.bmc.2023.117339_b1210","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1086\/324081","article-title":"A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria","volume":"33","author":"Shanks","year":"2001","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"10.1016\/j.bmc.2023.117339_b1215","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.trstmh.2004.01.013","article-title":"Treatment of acute vivax malaria with tafenoquine","volume":"99","author":"Nasveld","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.bmc.2023.117339_b1220","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1179\/2047773215Y.0000000013","article-title":"Killing the hypnozoite \u2013 drug discovery approaches to prevent relapse in Plasmodium vivax","volume":"109","author":"Campo","year":"2015","journal-title":"Pathog Glob Health."},{"key":"10.1016\/j.bmc.2023.117339_b1225","doi-asserted-by":"crossref","DOI":"10.14218\/ERHM.2019.00004","article-title":"Tafenoquine: A Breakthrough Drug for Radical Cure and Elimination of Malaria","author":"Gopi","year":"2019","journal-title":"Explor Res Hypothesis Med"},{"key":"10.1016\/j.bmc.2023.117339_b1230","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1086\/424508","article-title":"Randomized Trial of 3-Dose Regimens of Tafenoquine (WR238605) versus Low-Dose Primaquine for Preventing Plasmodium vivax Malaria Relapse","volume":"39","author":"Walsh","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b1235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/ph12030115","article-title":"Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria","volume":"12","author":"Mayence","year":"2019","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.bmc.2023.117339_b1240","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.vetpar.2016.12.008","article-title":"Artesunate-tafenoquine combination therapy promotes clearance and abrogates transmission of the avian malaria parasite Plasmodium gallinaceum","volume":"233","author":"Tasai","year":"2017","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.bmc.2023.117339_b1245","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)31285-1","article-title":"Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial","volume":"394","author":"Taylor","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2023.117339_b1250","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/AAC.00777-06","article-title":"In Vitro Activity of Tafenoquine against the Asexual Blood Stages of Plasmodium falciparum Isolates from Gabon, Senegal, and Djibouti","volume":"50","author":"Pradines","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b1255","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4269\/ajtmh.2003.69.542","article-title":"Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand","volume":"69","author":"Ponsa","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bmc.2023.117339_b1260","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.00354-09","article-title":"Randomized, Double-Blind Study of the Safety, Tolerability, and Efficacy of Tafenoquine versus Mefloquine for Malaria Prophylaxis in Nonimmune Subjects","volume":"54","author":"Nasveld","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b1265","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.tmaid.2017.05.008","article-title":"Tafenoquine for malaria prophylaxis in adults: An integrated safety analysis","volume":"17","author":"Novitt-Moreno","year":"2017","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b1270","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2147\/IDR.S151031","article-title":"Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data","volume":"12","author":"Hounkpatin","year":"2019","journal-title":"Infect Drug Resist."},{"key":"10.1016\/j.bmc.2023.117339_b1275","doi-asserted-by":"crossref","first-page":"296ra111","DOI":"10.1126\/scitranslmed.aaa6645","article-title":"A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria","volume":"7","author":"Phillips","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmc.2023.117339_b1280","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1473-3099(17)30139-1","article-title":"DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection","volume":"17","author":"Sulyok","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b1285","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/jix613","article-title":"A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation","volume":"217","author":"Murphy","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b1290","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2165\/00003495-200262090-00003","article-title":"Combination therapy for malaria: the way forward?","volume":"62","author":"Nosten","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2023.117339_b1295","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1021\/jm970401y","article-title":"Synthesis and Antimalarial Activity in Vitro and in Vivo of a New Ferrocene\u2212Chloroquine Analogue","volume":"40","author":"Biot","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b1300","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1021\/cb100322v","article-title":"The Antimalarial Ferroquine: Role of the Metal and Intramolecular Hydrogen Bond in Activity and Resistance","volume":"6","author":"Dubar","year":"2011","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2023.117339_b1305","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/jac\/dkg161","article-title":"In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogoou\u00e9 region of Gabon","volume":"51","author":"Atteke","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b1310","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1475-2875-5-11","article-title":"Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure","volume":"5","author":"Daher","year":"2006","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2023.117339_b1315","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0020-7519(02)00261-8","article-title":"Influence of CD4+CD25+ T cells on Plasmodium berghei NK65 infection in BALB\/c mice","volume":"33","author":"Long","year":"2003","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.bmc.2023.117339_b1320","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/s12936-016-1511-3","article-title":"A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study","volume":"15","author":"McCarthy","year":"2016","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2023.117339_b1325","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","article-title":"Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial","volume":"395","author":"van der Pluijm","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2023.117339_b1330","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(15)00079-1","article-title":"Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study","volume":"15","author":"Held","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b1335","doi-asserted-by":"crossref","first-page":"15896","DOI":"10.1038\/s41598-017-16154-2","article-title":"Ferroquine, the next generation antimalarial drug, has antitumor activity","volume":"7","author":"Kondratskyi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2023.117339_b1340","doi-asserted-by":"crossref","unstructured":"O\u2019Neill P, Barton V, Ward S, Chadwick J. 4-Aminoquinolines: Chloroquine, Amodiaquine and Next-Generation Analogues. In: Milestones in Drug Therapy. Vol 41. ; 2011:19-44. doi:10.1007\/978-3-0346-0480-2_2.","DOI":"10.1007\/978-3-0346-0480-2_2"},{"key":"10.1016\/j.bmc.2023.117339_b1345","doi-asserted-by":"crossref","first-page":"P70","DOI":"10.1186\/1475-2875-13-S1-P70","article-title":"Latter-stage preclinical developmental work on PL69\/DM1157","volume":"13","author":"Peyton","year":"2014","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2023.117339_b1350","unstructured":"Human trials begin for anti-malarial drug designed by PSU spinoff DesignMedix | Portland State University. Accessed June 12, 2022. https:\/\/www.pdx.edu\/news\/human-trials-begin-anti-malarial-drug-designed-psu-spinoff-designmedix."},{"key":"10.1016\/j.bmc.2023.117339_b1355","doi-asserted-by":"crossref","unstructured":"Biot C. Ferroquine: A New Weapon in the Fight Against Malaria. Curr Med Chem - Anti-Infect Agents. 3(2):135-147.","DOI":"10.2174\/1568012043354008"},{"key":"10.1016\/j.bmc.2023.117339_b1360","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1128\/AAC.01048-15","article-title":"Contrasting ex vivo efficacies of \u201creversed chloroquine\u201d compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates","volume":"59","author":"Wirjanata","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b1365","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40121-022-00605-z","article-title":"Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions","volume":"11","author":"Balevic","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.bmc.2023.117339_b1370","unstructured":"Early stage clinical trial of antimalarial drug begins. National Institutes of Health (NIH). Published September 10, 2018. Accessed June 13, 2022. https:\/\/www.nih.gov\/news-events\/news-releases\/early-stage-clinical-trial-antimalarial-drug-begins."},{"key":"10.1016\/j.bmc.2023.117339_b1375","unstructured":"Safety and Pharmacokinetics Study of DM1157 to Treat Malaria | Clinical Research Trial Listing (Malaria | Malaria Vaccines) (NCT03490162). Accessed June 13, 2022. https:\/\/www.centerwatch.com\/clinical-trials\/listings\/209080\/malaria-safety-pharmacokinetics-study-dm1157\/."},{"key":"10.1016\/j.bmc.2023.117339_b1380","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.exppara.2006.09.016","article-title":"In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models","volume":"115","author":"Snyder","year":"2007","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.bmc.2023.117339_b1385","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1473-3099(21)00004-9","article-title":"Arterolane-based combinations for the treatment of uncomplicated falciparum malaria in Kenyan children","volume":"21","author":"Varo","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b1390","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/cid\/cis475","article-title":"Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial","volume":"55","author":"Valecha","year":"2012","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"10.1016\/j.bmc.2023.117339_b1395","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nature02779","article-title":"Identification of an antimalarial synthetic trioxolane drug development candidate","volume":"430","author":"Vennerstrom","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2023.117339_b1400","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.pt.2019.05.002","article-title":"Ozonide Antimalarial Activity in the Context of Artemisinin-Resistant Malaria","volume":"35","author":"Giannangelo","year":"2019","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.bmc.2023.117339_b1405","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1021\/jm049040u","article-title":"Spiro and Dispiro-1,2,4-trioxolanes as Antimalarial Peroxides: Charting a Workable Structure\u2212Activity Relationship Using Simple Prototypes","volume":"48","author":"Dong","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117339_b1410","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S1473-3099(20)30929-4","article-title":"Arterolane\u2013piperaquine\u2013mefloquine versus arterolane\u2013piperaquine and artemether\u2013lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial","volume":"21","author":"Hamaluba","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b1415","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1086\/655831","article-title":"Arterolane, a New Synthetic Trioxolane for Treatment of Uncomplicated Plasmodium falciparum Malaria: A Phase II, Multicenter, Randomized, Dose-Finding Clinical Trial","volume":"51","author":"Valecha","year":"2010","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.bmc.2023.117339_b1420","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1128\/AAC.01305-09","article-title":"Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals","volume":"54","author":"F\u00fcgi","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b1425","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/AAC.00574-16","article-title":"Comparison of the Exposure Time Dependence of the Activities of Synthetic Ozonide Antimalarials and Dihydroartemisinin against K13 Wild-Type and Mutant Plasmodium falciparum Strains","volume":"60","author":"Yang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b1430","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1128\/AAC.00857-16","article-title":"Endoperoxide Drug Cross-Resistance Patterns for Plasmodium falciparum Exhibiting an Artemisinin Delayed-Clearance Phenotype","volume":"60","author":"Siriwardana","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117339_b1435","doi-asserted-by":"crossref","unstructured":"Abd-Rahman AN, Zaloumis S, McCarthy JS, Simpson JA, Commons RJ. Scoping Review of Antimalarial Drug Candidates in Phase I and II Drug Development. Antimicrob Agents Chemother. 66(2):e01659-21. doi:10.1128\/aac.01659-21.","DOI":"10.1128\/aac.01659-21"},{"key":"10.1016\/j.bmc.2023.117339_b1440","doi-asserted-by":"crossref","first-page":"eaap7847","DOI":"10.1126\/science.aap7847","article-title":"Uncovering the essential genes of the human malaria parasite Plasmodium falciparum by saturation mutagenesis","volume":"360","author":"Zhang","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bmc.2023.117339_b1445","unstructured":"WO2021204952A1.pdf. Accessed January 12, 2023. https:\/\/patentimages.storage.googleapis.com\/e1\/a9\/15\/1805084ab77adc\/WO2021204952A1.pdf."},{"key":"10.1016\/j.bmc.2023.117339_b1450","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(22)00294-8","article-title":"Effect of novel antimalarial ZY-19489 on Plasmodium falciparum viability in a volunteer infection study","volume":"22","author":"Radohery","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b1455","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1473-3099(21)00679-4","article-title":"Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study","volume":"22","author":"Barber","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2023.117339_b1460","doi-asserted-by":"crossref","first-page":"6715","DOI":"10.1038\/ncomms7715","article-title":"Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate","volume":"6","author":"Hameed","year":"2015","journal-title":"Nat Commun"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623001876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623001876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:23:28Z","timestamp":1760837008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089623001876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":292,"alternative-id":["S0968089623001876"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117339","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent developments in antimalarial drug discovery","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117339"}}